Mosaic ImmunoEngineering (CPMV) Stock Price, News & Analysis

Company Overview

Mosaic ImmunoEngineering (OTCMKTS:CPMV) is a development-stage biotechnology company focused on advancing immunotherapies and vaccine candidates through its proprietary nanoparticle platform. The company leverages virus-like particles derived from the cowpea mosaic virus (CPMV) to serve as both antigen carriers and immune stimulators, aiming to enhance the magnitude and durability of immune responses. By engineering these plant-based VLPs to display target antigens or adjuvant properties, Mosaic ImmunoEngineering seeks to create differentiated candidates for oncology indications and infectious disease prevention.

Operating out of the United States, Mosaic ImmunoEngineering is currently in preclinical stages of development. While detailed pipeline disclosures remain limited, the company highlights its platform’s flexibility to deliver protein antigens in a highly multivalent format, potentially improving efficacy over traditional formulations. Though still early in its corporate history, Mosaic ImmunoEngineering’s approach reflects growing interest in novel nanoparticle-based vaccine technologies, with the company positioning itself to explore collaborations or licensing arrangements as its candidates advance.

Key Stats

• Today's Range: $0.67 to $0.67
• 50-Day Range: $0.33 to $0.75
• 52-Week Range: $0.30 to $1.05
• Volume: N/A
• Average Volume: 50 shs
• Market Capitalization: $4.88 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Mosaic ImmunoEngineering Stock Analysis - MarketRank™

Mosaic ImmunoEngineering scored higher than 2% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Mosaic ImmunoEngineering.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Mosaic ImmunoEngineering is -7.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Mosaic ImmunoEngineering is -7.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.10% of the float of Mosaic ImmunoEngineering has been sold short.

Short Interest Ratio / Days to Cover

Mosaic ImmunoEngineering has a short interest ratio ("days to cover") of 3.86, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Mosaic ImmunoEngineering has recently increased by 54.64%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Mosaic ImmunoEngineering does not currently pay a dividend.

Dividend Growth

Mosaic ImmunoEngineering does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Mosaic ImmunoEngineering this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Mosaic ImmunoEngineering insiders have not sold or bought any company stock.

Percentage Held by Insiders

80.99% of the stock of Mosaic ImmunoEngineering is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Mosaic ImmunoEngineering has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/20/2026
• Today: 7/01/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:CPMV
• CIK: 836564
• Web: www.ptsc.com
• Phone: (657) 208-0890
• Fax: 760-547-2705
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.09)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$690 thousand
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -1,908.81%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.03) per share
• Price / Book: -0.65

Miscellaneous

• Outstanding Shares: 7,240,000
• Free Float: 1,377,000
• Market Cap: $4.88 million
• Optionable: Not Optionable
• Beta: -0.84